Netpharmalab Reaches €3 Million in 2022 and Anticipates a 16% Increase in 2023

The Spanish laboratory Netpharmalab, dedicated to executing analytical services in the production processes of the pharmaceutical industry, has reached a turnover of €3 million in 2022, and anticipates an increase of 16% by 2023, up to €3.5 million, according to indicates the general director of the group, Sergio Arroyo.

Looking ahead to 2024, the company plans to continue increasing its turnover to €5 million. In 2022, the group has incorporated AGQ laboratories as the majority shareholder, an agreement through which the group will increase its international presence to 25 new markets.

Specifically, Netpharmalab performs microbiological monitoring tasks, endotoxin, water and physical-chemical analysis, galenic development, or stability studies. The company does not have its own manufacturing but rather supervises pharmacological processes. In addition, it has a line of academic development for companies in the industry. 

Read more about Netpharmalab and find the latest financial news of the day with our companion app Born2Invest.

Netpharmalab plans to reach a turnover of €5 million in 2024

The company, which has 37 people on its staff, generates 80% of its turnover in the Spanish market and the remaining 20% ​​in various international markets, including Germany, the United Kingdom, France, India, and China. Following the incorporation of AGQ, Netpharmalab plans to increase its international turnover by between 20% and 50%.

The company has maintained organic growth throughout its history. Netpharmalab was founded in 2017 in Madrid, “due to the absence of a company that offered these services in the center of Spain: we moved to Madrid something that was only done in Barcelona.”

By 2023, the group plans to increase its market in the development and analysis of inhalation pharmaceuticals, as well as to increase its biologics service capabilities.

The company generates 80% of its turnover in the Spanish market

Netpharmalab has more than 500 square meters of laboratory, divided between an area for physicochemical analysis and another area for microbiological analysis. In addition, it has a specific area for stability chambers and another for work in sterile conditions.

AGQ Labs, the company’s majority shareholder for just over a month, is a Sevillian technology laboratory that performs specialized analyzes in various industries, including pharmaceuticals, agri-food, mining, and energy, among others. The company entered €53 million in 2022.

__

(Featured image by geralt via Pixabay)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in PlantaDoce, a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.